New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif Cancer Research UK, CRT and MRC to target cancer immunotherapies http://www.pharmaceutical-technology.com/news/newscancer-research-uk-crt-and-mrc-to-target-cancer-immunotherapies-5719058 http://www.pharmaceutical-technology.com/news/newscancer-research-uk-crt-and-mrc-to-target-cancer-immunotherapies-5719058 Cancer Research UK, Cancer Research Technology (CRT) and MRC Technology are set to collaborate in a bid to focus on cancer immunotherapies. Wed, 18 Jan 2017 00:00:00 GMT Malecare launches new mobile application Cancergraph to track cancer symptoms http://www.pharmaceutical-technology.com/news/newsmalecare-launches-new-mobile-application-cancergraph-to-track-cancer-symptoms-5719000 http://www.pharmaceutical-technology.com/news/newsmalecare-launches-new-mobile-application-cancergraph-to-track-cancer-symptoms-5719000 US-based men’s cancer survivor support and advocacy national non-profit organisation Malecare has launched a new mobile application, Cancergraph, which tracks cancer symptoms. Wed, 18 Jan 2017 00:00:00 GMT Eisai acquires manufacturing rights for API from Roche to treat insomnia http://www.pharmaceutical-technology.com/news/newseisai-acquires-manufacturing-rights-for-api-from-roche-to-treat-insomnia-5719024 http://www.pharmaceutical-technology.com/news/newseisai-acquires-manufacturing-rights-for-api-from-roche-to-treat-insomnia-5719024 Eisai has acquired the rights for manufacturing active pharmaceutical ingredients (API) for Japan from F Hoffman-La Roche for the insomnia treatment / anaesthesia induction agent flunitrazepam. Wed, 18 Jan 2017 00:00:00 GMT SMC rejects two indications of myeloma drugs Kyprolis and Darzalex in Scotland http://www.pharmaceutical-technology.com/news/newssmc-rejects-two-indications-of-myeloma-drugs-kyprolis-and-darzalex-in-scotland-5718068 http://www.pharmaceutical-technology.com/news/newssmc-rejects-two-indications-of-myeloma-drugs-kyprolis-and-darzalex-in-scotland-5718068 Drug approval body the Scottish Medicines Consortium (SMC) has rejected two life-prolonging indications of new myeloma drugs, Kyprolis (carfilzomib) and Darzalex (daratumumab), for use in the country. Tue, 17 Jan 2017 00:00:00 GMT EC amends marketing authorisation for Pharming’s Ruconest to include self-administration http://www.pharmaceutical-technology.com/news/newsec-amends-marketing-authorisation-for-pharmings-ruconest-to-include-self-administration-5718057 http://www.pharmaceutical-technology.com/news/newsec-amends-marketing-authorisation-for-pharmings-ruconest-to-include-self-administration-5718057 The European Commission (EC) has amended the marketing authorisation for Netherlands-based Pharming Group’s Ruconest (recombinant C1 esterase inhibitor) to include self-administration using the Ruconest administration kit. Tue, 17 Jan 2017 00:00:00 GMT New study finds benzodiazepines use increases stroke risk in people with Alzheimer’s disease http://www.pharmaceutical-technology.com/news/newsnew-study-finds-benzodiazepines-usage-increases-stroke-risks-in-people-with-alzheimers-disease-5716858 http://www.pharmaceutical-technology.com/news/newsnew-study-finds-benzodiazepines-usage-increases-stroke-risks-in-people-with-alzheimers-disease-5716858 A new study from the University of Eastern Finland has found the use of drugs such as benzodiazepine and benzodiazepine-like drugs was related to a 20% increased risk of stroke in patients with Alzheimer’s disease. Tue, 17 Jan 2017 00:00:00 GMT US FDA extends review period for Eli Lilly and Incyte’s rheumatoid arthritis treatment http://www.pharmaceutical-technology.com/news/newsus-fda-extends-review-period-for-eli-lilly-and-incytes-rheumatoid-arthritis-treatment-5716742 http://www.pharmaceutical-technology.com/news/newsus-fda-extends-review-period-for-eli-lilly-and-incytes-rheumatoid-arthritis-treatment-5716742 The US Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for Eli Lilly and Incyte’s investigational baricitinib used to treat patients suffering from moderate-to-severe rheumatoid arthritis (RA). Mon, 16 Jan 2017 00:00:00 GMT M Pharmaceutical to develop new topical drug product for FSD http://www.pharmaceutical-technology.com/news/newsm-pharmaceutical-to-develop-new-topical-drug-product-for-fsd-5717080 http://www.pharmaceutical-technology.com/news/newsm-pharmaceutical-to-develop-new-topical-drug-product-for-fsd-5717080 Canadian-headquartered M Pharmaceutical has announced plans to continue advancing the development of a topical drug product as part of its planned acquisition of 40 J's. Mon, 16 Jan 2017 00:00:00 GMT Merck to leverage Palantir’s data analytics capabilities http://www.pharmaceutical-technology.com/news/newsmerck-to-leverage-palantirs-data-analytics-capabilities-5717200 http://www.pharmaceutical-technology.com/news/newsmerck-to-leverage-palantirs-data-analytics-capabilities-5717200 Merck has collaborated with Palantir to leverage the latter’s advanced data analytics capabilities to help it develop and deliver medicines to patients. Mon, 16 Jan 2017 00:00:00 GMT Orthocell collaborates with J&J’s DePuy Synthes for Ortho-ATI approach http://www.pharmaceutical-technology.com/news/newsorthocell-collaborates-with-jjs-depuy-synthes-for-ortho-ati-approach-5716238 http://www.pharmaceutical-technology.com/news/newsorthocell-collaborates-with-jjs-depuy-synthes-for-ortho-ati-approach-5716238 Regenerative medicine company Orthocell has announced plans to collaborate with DePuy Synthes Products, part of the Johnson & Johnson (J&J) family of companies, for its Ortho-ATI stem-cell approach. Fri, 13 Jan 2017 00:00:00 GMT US FDA accepts Mylan’s BLA for proposed trastuzumab product http://www.pharmaceutical-technology.com/news/newsus-fda-accepts-mylans-bla-for-proposed-trastuzumab-product-5716282 http://www.pharmaceutical-technology.com/news/newsus-fda-accepts-mylans-bla-for-proposed-trastuzumab-product-5716282 Biocon and Mylan have announced acceptance of the latter’s biologics licence application (BLA) by the US Food and Drug Administration (FDA) for MYL-1401O, a proposed biosimilar trastuzumab. Fri, 13 Jan 2017 00:00:00 GMT Deals this week: Macrophage Pharma, Bioleaders, Corbin Therapeutics http://www.pharmaceutical-technology.com/news/newsdeals-this-week-macrophage-pharma-bioleaders-corbin-therapeutics-5715076 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-macrophage-pharma-bioleaders-corbin-therapeutics-5715076 UK-based immune-oncology company Macrophage Pharma has closed a series A equity financing round that raised £9m ($11.05m) with participation from CRT Pioneer Fund, Novo Seeds, and Aglaia Biomedical Ventures. Fri, 13 Jan 2017 00:00:00 GMT US FDA grants fast track designation for Starpharma’s VivaGel treatment http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-starpharmas-vivagel-bv-treatment-5716295 http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-starpharmas-vivagel-bv-treatment-5716295 The US Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) and fast track designation for Australian-based Starpharma’s VivaGel treatment. Fri, 13 Jan 2017 00:00:00 GMT M&As this week: Dendreon Pharmaceuticals, Agile Pharma, Takeda Pharmaceutical Company http://www.pharmaceutical-technology.com/news/newsmas-this-week-dendreon-pharmaceuticals-inc-agile-pharma-bv-takeda-pharmaceutical-company-limited-5715380 http://www.pharmaceutical-technology.com/news/newsmas-this-week-dendreon-pharmaceuticals-inc-agile-pharma-bv-takeda-pharmaceutical-company-limited-5715380 Valeant Pharmaceuticals International subsidiary Dendreon Pharmaceuticals will be acquired by Sanpower Group. Fri, 13 Jan 2017 00:00:00 GMT UK scientists discover new chemical inhibitor of cancer stress signal http://www.pharmaceutical-technology.com/news/newsuk-scientists-discover-new-chemical-inhibitor-of-cancer-stress-signal-5715223 http://www.pharmaceutical-technology.com/news/newsuk-scientists-discover-new-chemical-inhibitor-of-cancer-stress-signal-5715223 Scientists from the Institute of Cancer Research (ICR), London, have discovered a new chemical inhibitor that blocks a crucial system used by cancer cells to cope with stress. Thu, 12 Jan 2017 22:05:00 GMT Pitt and Bayer to advance research for heart, lung and blood disease indications http://www.pharmaceutical-technology.com/news/newspitt-bayer-to-advance-research-for-heart-lung-and-blood-disease-indications-5715270 http://www.pharmaceutical-technology.com/news/newspitt-bayer-to-advance-research-for-heart-lung-and-blood-disease-indications-5715270 The University of Pittsburgh (Pitt) and Bayer have collaborated to advance research for heart, lung and blood disease indications. Thu, 12 Jan 2017 00:00:00 GMT New study finds antidepressant use increases hip fracture risk in people with Alzheimer’s disease http://www.pharmaceutical-technology.com/news/newsnew-study-finds-antidepressant-use-increases-hip-fracture-risk-in-people-with-alzheimers-disease-5715235 http://www.pharmaceutical-technology.com/news/newsnew-study-finds-antidepressant-use-increases-hip-fracture-risk-in-people-with-alzheimers-disease-5715235 A new study from the University of Eastern Finland has found that the use of antidepressants nearly doubles the risk of hip fracture among community-dwelling people with Alzheimer’s disease. Thu, 12 Jan 2017 00:00:00 GMT Valeant to sell Dendreon to China’s Sanpower for $819.9m http://www.pharmaceutical-technology.com/news/newsvaleant-to-sell-dendreon-to-chinas-sanpower-for-8199m-5714173 http://www.pharmaceutical-technology.com/news/newsvaleant-to-sell-dendreon-to-chinas-sanpower-for-8199m-5714173 Canada’s Valeant Pharmaceuticals’ affiliate has entered an agreement to sell its equity interests in Dendreon Pharmaceuticals to China’s Sanpower Group for $819.9m. Wed, 11 Jan 2017 00:00:00 GMT Zambon and Seqirus partner for Parkinson's disease product in Australia and New Zealand http://www.pharmaceutical-technology.com/news/newszambon-seqirus-partner-for-parkinsons-disease-product-in-australia-and-new-zealand-5714202 http://www.pharmaceutical-technology.com/news/newszambon-seqirus-partner-for-parkinsons-disease-product-in-australia-and-new-zealand-5714202 Italian company Zambon and Australian-based Seqirus have collaborated for Parkinson's disease (PD) product, Xadago, in Australia and New Zealand. Wed, 11 Jan 2017 00:00:00 GMT EC ratifies positive opinion for PTC’s Translarna marketing authorisation renewal http://www.pharmaceutical-technology.com/news/newsec-ratifies-positive-opinion-for-ptcs-translarna-marketing-authorisation-renewal-5714191 http://www.pharmaceutical-technology.com/news/newsec-ratifies-positive-opinion-for-ptcs-translarna-marketing-authorisation-renewal-5714191 The European Commission (EC) has ratified a positive opinion for the annual renewal of PTC Therapeutics’ Translarna (ataluren) marketing authorisation for the treatment of nonsense mutation duchenne muscular dystrophy (nmDMD). Wed, 11 Jan 2017 00:00:00 GMT